AMGN · 10-Q · 2026Q3 · Full report
Liquidity and Debt Position
AMGEN INC · 2026-11-04 · Importance 64 · Surprise 56 · Contradicted
At September 30, 2026, cash and cash equivalents were $13.190 billion, up from $9.129 billion at December 31, 2025; total assets were $96.048 billion. Current and long-term debt were $2.398 billion and $51.609 billion, respectively, compared with $4.599 billion and $50.005 billion at year-end 2025. During the first nine months of 2026, Amgen issued $4.0 billion of notes and repaid $3.9 billion of debt; it also repurchased $324 million principal amount of debt for $233 million, recording a $90 million gain on extinguishment. Amgen had no borrowings under its $4.0 billion revolving credit facility at September 30, 2026 and was in compliance with applicable covenants.
Key facts
- In the first quarter of 2026, Amgen extended its $4.0 billion syndicated unsecured revolving credit facility by one year to March 2029; no amounts were outstanding at September 30, 2026 or December 31, 2025. source
- Amgen had cash and cash equivalents of $13.190 billion at September 30, 2026, compared with $9.129 billion at December 31, 2025. source
- Amgen extended its revolving credit facility by one year to March 2029; no amounts were outstanding as of September 30, 2026 or December 31, 2025. source
- Amgen repaid $3.1 billion of debt during the three months ended September 30, 2026, including repayment in full of a $1.8 billion term loan and $1.25 billion principal amount of 2.60% 2026 Notes. source
- Amgen cash and cash equivalents were $13.190 billion at September 30, 2026, compared with $9.129 billion at December 31, 2025. source
- Amgen total assets were $96.048 billion at September 30, 2026, compared with $90.586 billion at December 31, 2025. source
- Amgen long-term debt was $51.609 billion at September 30, 2026, compared with $50.005 billion at December 31, 2025. source
- Amgen stockholders' equity was $14.352 billion at September 30, 2026, compared with $8.658 billion at December 31, 2025. source
Impact estimates
| metric | direction | stage | expected | basis |
|---|---|---|---|---|
| assets | positive | realized | +5.7% | Amgen total assets were $96.048 billion at September 30, 2026, compared with $90.586 billion at December 31, 2025. |
| cash | negative | realized | -4.3% | Cash used in financing activities in the nine months ended September 30, 2026 was primarily for $3.9 billion of debt repayment, $233… |
| cash | positive | realized | +4.2% | Amgen had cash and cash equivalents of $13.190 billion at September 30, 2026, compared with $9.129 billion at December 31, 2025. |
| cash | positive | realized | +4.2% | Cash used in financing activities in the nine months ended September 30, 2026 was primarily for $3.9 billion of debt repayment, $233… |
| liability | negative | realized | -4.2% | Cash used in financing activities in the nine months ended September 30, 2026 was primarily for $3.9 billion of debt repayment, $233… |
| cash | negative | realized | -4.1% | Cash used in financing activities in the nine months ended September 30, 2026 was primarily for $3.9 billion of debt repayment, $233… |
| liability | positive | realized | +4.1% | Cash used in financing activities in the nine months ended September 30, 2026 was primarily for $3.9 billion of debt repayment, $233… |
| liability | negative | realized | -1.7% | Amgen long-term debt was $51.609 billion at September 30, 2026, compared with $50.005 billion at December 31, 2025. |
| liability | positive | realized | +0.6% | Amgen's total carrying value of debt was $54.007 billion at September 30, 2026, compared with $54.604 billion at December 31, 2025. |
| cash | negative | realized | -0.2% | Cash used in financing activities in the nine months ended September 30, 2026 was primarily for $3.9 billion of debt repayment, $233… |
| liability | positive | realized | +0.2% | Cash used in financing activities in the nine months ended September 30, 2026 was primarily for $3.9 billion of debt repayment, $233… |